[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"premature-ventricular-contraction-pvc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:premature-ventricular-contraction-pvc":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,75,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100302515","phase-4-use-of-adenosine-to-determine-the-electrophysiological-mechanism-of-premature-ventricular-contractions-100302515",false,"NCT03218137","Use of Adenosine to Determine the Electrophysiological Mechanism of Premature Ventricular Contractions","Inclusion Criteria:\n\n* Diagnosis of premature ventricular contractions (PVCs)\n* Scheduled to undergo an electrophysiology study with the intention of performing cardiac ablation for the treatment of PVCs\n* Male or female between the ages of 18 and 70 years\n* Capable of giving informed consent\n\nExclusion Criteria:\n\n* Any structural heart disease\n* Coronary artery disease (≥ 70% stenosis)\n* Current treatment with anti-arrhythmic drugs\n* Pregnant\n* Asthma (if administering adenosine)",true,"ALL","18 Years","70 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Unblinded, controlled, non-randomized, mechanistic study to determine whether physiological mechanisms underlying PVC are sensitive to adenosine. One hundred subjects undergoing clinically-indicated, standard-of-care cardiac electrophysiology study (EPS) procedure for PVCs will receive adenosine and\u002For verapamil to learn if their arrhythmias are inducible similarly to sustained ventricular tachycardia.",[27],"Premature Ventricular Contraction (PVC)",[29,30],"Subjects","diagnosed","RECRUITING","2026-06-18",{"date":34,"type":35},"2026-06-23","ACTUAL",{"date":37,"type":35},"2017-02-13",{"date":39,"type":21},"2027-12-31",{"name":41,"class":42},"Weill Medical College of Cornell University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":43},"100627184","catheter-ablation-versus-anti-arrhythmic-drugs-for-premature-ventricular-complexes-100627184","NCT07445334","Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes","Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes (CAAD-PVC): A Randomised Controlled Trial Pilot Study","CAAD-PVC","Inclusion Criteria:\n\n* Premature ventricular complex burden of at least 10%, as determined by multiday (\\>24-hour) heart rhythm monitoring\n* Normal left ventricular ejection fraction\n* Aged ≥18 years.\n\nExclusion Criteria:\n\n* Unable or unwilling to provide informed consent or comply with study requirements including study investigations and follow-up, medical adherence, completion of intervention.\n* Women who are pregnant or breast feeding.\n* Life expectancy ≤ 12 months.\n* Ventricular tachycardia (VT) that is inducible lasting 10 seconds or more; spontaneously occurring lasting 30 seconds or more or not hemodynamically tolerated); or 10 or more episodes of non-sustained ventricular tachycardia (defined as more than five sequential beats, lasting no more than 10 seconds) in 24 hours during ambulatory heart rhythm recording.\n* Structural heart disease including clinically significant coronary artery, valvular disease or clinically significant myocardial replacement.\n* Known cardiac channelopathies (e.g. Catecholaminergic polymorphic ventricular tachycardia (CPVT), long- or short QT syndrome, Brugada syndrome).\n* Responsible primary care or other responsible physician believes it is not appropriate to participate in the study or unable to complete the study procedures, e.g. concomitant illness, physical impairment or mental condition which could interfere with the conduct of the study including outcome assessments.",{"count":53,"type":21},40,[55],"NA","Premature ventricular complexes (PVCs) are extra, abnormal heart beats arising from the ventricles of the heart and are the most common ventricular arrhythmia. PVCs can be treated with medication or with a procedure called catheter ablation. It is not known which provides a better cure or provides better quality of life. The purpose of this research project is to study the best way to treat PVCs by comparing the use of medication to catheter ablation to assess which approach is better at reducing symptoms and improving quality of life.",[58,27,59],"Premature Ventricular Complexes","Premature Ventricular Beats",[61,62,58,63,64],"PVC","catheter ablation","anti-arrhythmic medication","beta blocker","NOT_YET_RECRUITING","2026-02-24",{"date":68,"type":35},"2026-03-03",{"date":70,"type":21},"2026-03-01",{"date":72,"type":21},"2028-03-01",{"name":74,"class":42},"Western Sydney Local Health District",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":43},"100609895","disrupted-sleep-and-concurrent-ectopy-or-atrial-fibrillation-100609895","NCT07220525","Disrupted Sleep and Concurrent Ectopy or Atrial Fibrillation","DISCRETE AF","Inclusion Criteria:\n\n* Are age 21 years or older\n* Have a HGNS device implanted for obstructive sleep apnea and followed up at UCSF Health\n* Are willing to abstain from using the upper airway stimulation device for no more than two consecutive days as instructed over the 14-day trial period\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Currently pregnant or trying to get pregnant\n* Are currently taking class 1 or 3 anti-arrhythmic medications\n* Have a history of permanent AF or expected to have continuous AF throughout the study period\n* Have congenital heart disease\n* Ventricular pacing \\>40%\n* Are unable to read or sign to provide informed consent","21 Years",{"count":20,"type":21},[55],"Whereas the available evidence mostly supports chronic sleep disruption as a risk factor for incident AF, less is known about the near-term risk of a discrete atrial fibrillation (AF) episode following a night of disrupted or poor-quality sleep. This prospective, randomized, case-crossover study aims to examine the acute effects of sleep disruption on clinically relevant cardiac ectopy pertinent to AF.",[87,27,88,89],"Obstructive Sleep Apnea","Atrial Fibrillation (AF)","Premature Atrial Contraction",[91,92,93,94,89,95],"Sleep Apnea","Hypoglossal Nerve Stimulation Device","Atrial Fibrillation","Upper Airway Stimulation","Premature Ventricular Contraction","2026-01-21",{"date":98,"type":35},"2026-01-23",{"date":100,"type":35},"2025-12-15",{"date":102,"type":21},"2027-06-01",{"name":104,"class":42},"University of California, San Francisco",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":116,"conditions":117,"keywords":123,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":138},"100589079","flecainide-in-idiopathic-premature-ventricular-contractions-and-related-cardiomyopathy-100589079","NCT06949748","Flecainide in Idiopathic Premature Ventricular Contractions and Related Cardiomyopathy","UNIFLECA Study: Prospective Cohort Study on Flecainide's Impact on Persistent High Premature Ventricular Contraction Burden and PVC-Induced Cardiomyopathy","UNIFLECA","Inclusion Criteria:\n\n* Frequent idiopathic PVCs (burden \\>5% on multiple 24-hour Holter ECG recordings)\n* Normal cardiac structure and function on echocardiography\n* No late gadolinium enhancement or myocardial scar on cardiac MRI\n* Normal coronary angiography (excluding ischemic cardiomyopathy)\n* Normal serum electrolytes and renal function\n* Willingness to comply with follow-up schedule and drug titration\n\nExclusion Criteria:\n\n* Structural heart disease\n* Ischemic heart disease (confirmed by angiography)\n* History of sustained ventricular arrhythmias\n* Left ventricular ejection fraction (LVEF) \\\u003C40% at baseline\n* Brugada syndrome, long QT syndrome, or other channelopathies\n* Contraindications to class IC agents\n* Use of concurrent antiarrhythmics or proarrhythmic drugs",{"count":114,"type":21},300,"OBSERVATIONAL","The UNIFLECA study is a prospective, single-arm, observational cohort evaluating the efficacy, safety, and tolerability of flecainide (in the form of Sanocard) in adults with frequent idiopathic premature ventricular contractions (PVCs) and suspected PVC-induced cardiomyopathy (PVCi-CMP). Frequent PVCs-defined as a burden \\>5% on two separate 24-hour Holter recordings-are increasingly recognized as a cause of reversible systolic dysfunction in patients without structural heart disease.\n\nParticipants undergo a comprehensive baseline evaluation including echocardiography, occasionally cardiac MRI, and coronary angiography or equivalent testing to confirm the absence of structural abnormalities. Patients are enrolled only if they are ineligible or unwilling to undergo catheter ablation, and have no contraindications to flecainide.\n\nFlecainide therapy is initiated at a starting dose of 100 mg\u002Fday and titrated up to 200 mg\u002Fday, guided by ECG findings, symptom response, and QRS duration. Regular follow-up occurs at three-month intervals over three years, with periodic 24-hour Holter monitoring and assessment of symptoms, LVEF, and adverse events.\n\nThe primary outcome is the reduction in PVC burden. Secondary outcomes include improvement in LVEF, symptom relief (measured by structured questionnaires), adverse effects, and long-term treatment adherence. The study aims to generate real-world data on the non-invasive management of PVCs with flecainide and explore its role as an alternative to ablation in carefully selected patients.",[59,58,27,118,119,120,121,122],"Arrhythmia Ventricular","Ventricular Dysfunction, Left","Ventricular Dysfunction","Cardiomyopathies, Secondary","Cardiomyopathies",[124,125,111,126,61,95,127,128],"Flecainide","Sanocard","PVC induced CMP","Outflow Tract PVC","NonOutflow Tract PVC","2025-06-27",{"date":131,"type":35},"2025-07-02",{"date":133,"type":35},"2024-04-26",{"date":135,"type":21},"2027-12-01",{"name":137,"class":42},"University of Athens",6]